Similarly, in a single arm phase II study of nintedanib in patients with refractory oesophago-gastric cancers, 6 of 32 patients (19%) were progression-free at 6 months, however, FGFR2 alterations (which were detected in 18% of patients), were not predictive of progression-free survival (PFS) [75]. Here, FGFR2 is linked to gastric cancer.